- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04937673
The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Camrelizumab Combined With Chemotherapy for Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma:A Phase II Clinical Study to Explore the Relationship Between Biomarkers and Efficacy
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Beijing
-
Beijing, Beijing, Porcelana, 100142
- Department of GI Oncology, Peking University Cancer Hospital,
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age: 18-75 years old, male or female;
- Esophageal squamous cell carcinoma was confirmed by pathology (except for cervical and Suprathoracic tumors that could not be operated);
- Patients with resectable esophageal squamous cell carcinoma with clinical stage T3-T4a or TxN + M0 (except T4b);
- ECOG PS score was 0-1;
- There was at least one measurable lesion (according to recist1.1) or unmeasurable lesion that could be evaluated, and the imaging diagnosis time was ≤ 21 days;
- The expected survival time was more than 3 months;
The function of the main organs was normal, and there were no serious blood, heart, lung, liver, kidney, bone marrow and other functional abnormalities and immunodeficiency diseases. The laboratory examination meets the following requirements:
- Hemoglobin (Hb) ≥ 90g / L;
- WBC ≥ 3.0 × 109/L; Neutrophil count (NEUT) ≥ 1.5 × 109/L;
- Platelet count (PLT) ≥ 100 × 109/L;
- Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance rate ≥ 50 ml / min (Cockcroft Gault formula);
- Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN);
- The levels of AST and ALT were less than 2.5 times the upper limit of normal (ULN);
There was no active bleeding or thrombosis
- International normalized ratio INR ≤ 1.5 × ULN;
- Partial thromboplastin time APTT ≤ 1.5 × ULN;
- Prothrombin time Pt ≤ 1.5ULN;
- The patients with normal or mild to moderate abnormal lung function (VC% > 60%, FEV1 > 1.2L, FEV1% > 40%, DLco> 40%) could tolerate esophagectomy;
- The fertile female subjects were required to conduct blood pregnancy test within 72 hours before the first administration, and the result was negative, and voluntarily used appropriate contraceptive methods during the observation period and within 90 days after the last administration of the study drug; For men, surgical sterilization or consent to appropriate contraceptive methods during the observation period and within 90 days after the last administration of the study drug should be used.
- The subjects voluntarily joined the study and signed the informed consent form (ICF);
- The patients with good compliance were expected to follow up the efficacy and adverse events / reactions according to the protocol requirements.
Exclusion Criteria:
- Subjects who have received or are receiving additional chemotherapy, radiotherapy, targeted or immunotherapy;
- Any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement therapy)); The subjects with childhood asthma who had been completely relieved and did not need any intervention or vitiligo in adulthood could be included, but the subjects who needed bronchodilator for medical intervention could not be included;
- Patients with congenital or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500 IU / ml), hepatitis C (HCV antibody positive and HCV-RNA higher than the detection limit of the analytical method), or co infection of hepatitis B and hepatitis C;
- Immunosuppressive drugs were used within 14 days before the first use of the study drug, excluding nasal and inhaled corticosteroids or physiological doses of systemic corticosteroids;
- Live attenuated vaccine was inoculated within 4 weeks before the first administration or during the study period;
- Patients with hypertension who can not be reduced to normal range after antihypertensive drug treatment (systolic blood pressure ≤ 140 mmHg / diastolic blood pressure ≤ 90 mmHg);
- Subjects with uncontrollable clinical cardiac symptoms or diseases, such as (1) heart failure of NYHA II or above (2) unstable angina pectoris (3) myocardial infarction within 1 year (4) clinically significant supraventricular or ventricular arrhythmia requiring clinical intervention;
- Severe infection (e.g. need for intravenous antibiotics, antifungal or antiviral drugs) occurred within 4 weeks before the first administration, or fever of unknown origin > 38.5% occurred during the screening period / before the first administration;
- History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation is known;
- Pregnant or lactating women; The fertile subjects were unwilling or unable to take effective contraceptive measures;
- Other malignant tumors were found in the past or at the same time, but the cured basal cell carcinoma of skin, carcinoma in situ of cervix and carcinoma in situ of breast were excluded;
- Known to have allergic history to the drug components of this protocol;
- Other situations considered unsuitable by the researchers.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Camrelizumab+ Paclitaxel+ Cisplatin
The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1.
Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation).
At the end of the treatment, the patients were followed up for safety and effectiveness.
|
Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks. Paclitaxel: 80 mg / m2, intravenous drip for 180 minutes, D1, D8, repeated every 3 weeks. Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks. |
Experimental: Camrelizumab+ Albumin bound paclitaxel+ Cisplatin
The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1.
Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation).
At the end of the treatment, the patients were followed up for safety and effectiveness.
|
Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks. Albumin bound paclitaxel: 130 mg / m2, intravenous drip for 30 minutes, D1, D8, repeated every 3 weeks. Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
biomarkers related to pCR
Periodo de tiempo: 9 weeks
|
t has a good value in predicting the efficacy of immunotherapy, and is helpful for the accurate formulation of treatment plan and the accurate evaluation of prognosis of patients with esophageal cancer.
|
9 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Objective Response Rate
Periodo de tiempo: 9 weeks
|
Assess ORR, defined as Investigator-assessed CR + PR, per RECIST 1.1.
|
9 weeks
|
Disease Control Rate
Periodo de tiempo: 9 weeks
|
Percentage of patients with CR/PR/SD in the number of patients that whose tumour can be evaluated.
|
9 weeks
|
Disease free survival
Periodo de tiempo: Time from randomization to patient's tumor progression or death
|
The DFS will be defined as the time of patients alive without local recurrence or distant metastasis of disease from the date of the administration of treatment.
|
Time from randomization to patient's tumor progression or death
|
Overall Survival
Periodo de tiempo: The time from the beginning of randomization to death due to any cause.
|
OS is defined as the time from registration to death due to any cause, or censored at date last known alive.
Measured by the method of Kaplan and Meier
|
The time from the beginning of randomization to death due to any cause.
|
Safety
Periodo de tiempo: from first treatment to 90 days after esophagectomy
|
Adverse events
|
from first treatment to 90 days after esophagectomy
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Anticipado)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias por sitio
- Neoplasias Glandulares y Epiteliales
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Neoplasias de Cabeza y Cuello
- Enfermedades esofágicas
- Neoplasias De Células Escamosas
- Neoplasias Esofágicas
- Carcinoma
- Carcinoma De Células Escamosas
- Carcinoma de células escamosas de esófago
- Mecanismos moleculares de acción farmacológica
- Agentes antineoplásicos
- Moduladores de tubulina
- Agentes antimitóticos
- Moduladores de mitosis
- Agentes antineoplásicos, fitogénicos
- Paclitaxel
- Cisplatino
- Paclitaxel unido a albúmina
Otros números de identificación del estudio
- MA-EC-II-005
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Camrelizumab+ Paclitaxel+ Cisplatin
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.DesconocidoCáncer de pulmón de células no pequeñasPorcelana
-
Korea Cancer Center HospitalTerminadoNEOPLASIAS CERVICALESCorea, república de
-
The First Affiliated Hospital with Nanjing Medical...Aún no reclutandoCarcinoma de células escamosas de esófago
-
Guangdong Association of Clinical TrialsAún no reclutandoCáncer de pulmón de células no pequeñas
-
Zhejiang Cancer HospitalDesconocidoCáncer de esófagoPorcelana
-
Ying LinReclutamientoCáncer de mama Her-2 negativo | Mutación del gen HRRPorcelana
-
Henan Cancer HospitalReclutamientoSarcoma de tejido blandoPorcelana
-
Guangzhou Institute of Respiratory DiseaseJiangsu HengRui Medicine Co., Ltd.; BGI-ShenzhenTerminadoCarcinoma de células escamosas de esófago | InmunoterapiaPorcelana
-
Di WuReclutamiento
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... y otros colaboradoresAún no reclutandoCáncer de cuello uterino | Preservación de la Fertilidad | Quimioinmunoterapia neoadyuvantePorcelana